RxSight, Inc. [●] Shares of Common Stock, par value $0.001 per share Underwriting AgreementRxSight, Inc. • July 26th, 2021 • Ophthalmic goods • New York
RxSight, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [•] shares of common stock, par value $0.001 per share (the “Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [•] shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
TERMINATION AGREEMENTTermination Agreement • July 26th, 2021 • RxSight, Inc. • Ophthalmic goods • California
THIS TERMINATION AGREEMENT (this “Agreement”) is effective as of the closing of the Public Offering (as defined below), by and between RxSight, Inc., a Delaware corporation (“Company”), and Yelroc Consulting, Inc., an entity (“Consultant”). All capitalized terms used but not defined herein shall have the corresponding meanings ascribed such terms in that certain Consulting Agreement dated as of January 1, 2019, as amended (the “Consulting Agreement”).
CONSENT AND FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENTConsent And • July 26th, 2021 • RxSight, Inc. • Ophthalmic goods • California
THIS CONSENT AND FIRST AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of July 6, 2021 (the “Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (in its individual capacity, “Oxford”; and in its capacity as Collateral Agent, “Collateral Agent”), the Lenders listed on Schedule 1.1 thereof from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), RXSIGHT, INC., a California corporation with offices located at 100 Columbia, Aliso Viejo, CA 92656 (“Existing Borrower”) and RXSIGHT, INC., a Delaware corporation with offices located at 100 Columbia, Aliso Viejo, CA 92656 (“New Borrower”).
SHARE FORFEITURE AND RELEASE AGREEMENTShare Forfeiture and Release Agreement • July 26th, 2021 • RxSight, Inc. • Ophthalmic goods • Delaware
THIS SHARE FORFEITURE AND RELEASE AGREEMENT (this “Agreement”) is made and entered into as of July 23, 2021 (the “Effective Date”) by and among RXSIGHT, INC., a Delaware corporation (the “Company”) and DANIEL M. SCHWARTZ, a natural person (“Maker”).
